• Criptomoedas
  • Mercados de Previsão
  • Notícias
  • Trading Agêntico
  • Artigos
  • Ligas

Pesquisar Criptomoedas

Criptomoedas em tendência

CoinRithm

Empresa

Entidade legal
Bees-x Limited
Número da empresa
13308136
Constituída em
England and Wales
Sede registrada
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm é um serviço de informação e pesquisa operado pela Bees-x Limited. Não é autorizado pela Financial Conduct Authority (FCA) a realizar atividades reguladas, e nada neste site constitui aconselhamento financeiro.

Explorar

CriptomoedasMercados de PrevisãoNotíciasArtigosAgent ArenaLigas

Recursos

Painel de ControleComércio SimuladoTrading AgênticoCarteiraLista de ObservaçãoConfigurações

Empresa

Sobre NósMetodologiaTermos de UsoPolítica de PrivacidadePolítica de CookiesAviso Legal

Suporte

Apoio ao ClienteFAQKit para desenvolvedoresDocumentação MCP

Redes Sociais

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Direitos reservados.
Disponível no Google PlayBaixar na App Store
  • Início
  • MercadosMercados de Previsão
  • Notícias
  • Painel de Controle
  1. Mercados de Previsão
  2. Health & Medicine
  3. Will the FDA approve any psychedelic substance for medical use this year?
Will the FDA approve any psychedelic substance for medical use this year?

Will the FDA approve any psychedelic substance for medical use this year?

5.0% (24h)Health & MedicineOne-Off6m
KalshiKalshiVerificar disponibilidadeKYC obrigatório2% de taxa
Probabilidade implícita atual
Sim
Sim 32%-5.0%
Qualidade do mercado

28 / 100

Baixa qualidade
Volume 24h

12 €

Liquidez

712,5 €

Baixa liquidez
Compra / Venda

30.0% / 33.0%

Spread

10.0%

Spread amplo
Dados do mercado

Atualizado há 3 minutos

17/07/25, 14:001/01/27, 4:59

Tendências

Resultado24hProbabilidade

Resultado escolhido

Yes32%

Regras

If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.

Kalshi
  • Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.
  • Important information: For purposes of this Contract:
  • The listed substances are illustrative, not exhaustive.
  • Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.
  • "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product.

Mercados Relacionados

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3 mil €
Sim: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6 mil €
Sim: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7 mil €
Sim: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3 mil €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Ativos nestes tópicos

BitcoinBTC$62,867.10+2.52%EthereumETH$1,658.07+1.88%SolanaSOL$65.28+1.86%DogecoinDOGE$0.085+1.73%XRPXRP$1.12+0.74%BNBBNB$596.82+1.84%

Notícias Relacionadas

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Regras

If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.

Kalshi
  • Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.
  • Important information: For purposes of this Contract:
  • The listed substances are illustrative, not exhaustive.
  • Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.
  • "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product.